A phase I trial to assess the effect of micro-dosing of lysergic acid diethylamide (LSD) on the sleep.
Hoba, a Danish biotech from Novo, raises $25M to crack into difficult pain and hearing loss fields
Novo Holdings-founded biotech Hoba Therapeutics has raised $25 million in the first close of a Series A financing to bankroll its investigational medicines for pain